Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

10.21 +0.73 (+7.70%)
Streaming Delayed Price Updated: 10:39 AM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MeiraGTx Holdings plc - Ordinary Shares

< Previous 1 2 Next >
News headline image
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property
News headline image
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary... 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx to Participate in Upcoming Investor Conferences
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of... 
From MeiraGTx
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.